Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

Michael Mullin1, James McClory1, Winston Haynes1

  • 1LabGenius, London, UK.

Mabs
|April 26, 2024
PubMed
Summary

Camelid-derived variable heavy domain of heavy chain (VHH) antibodies offer modularity for constructing bispecific antibodies. Machine learning aids in optimizing VHH antibody development for enhanced therapeutic quality and performance.